LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "q2w" as a keyword



Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Sign Up to like & get
recommendations! Published in 2017 at "Annals of Oncology"

DOI: 10.1093/annonc/mdx235

Abstract: Abstract Background Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation… read more here.

Keywords: benefit; q2w; safety; risk profile ... See more keywords

P080 Bimekizumab efficacy and impact on pain in moderate-to-severe hidradenitis suppurativa: results from BE HEARD I and II

Sign Up to like & get
recommendations! Published in 2024 at "British Journal of Dermatology"

DOI: 10.1093/bjd/ljae090.107

Abstract: Hidradenitis suppurativa (HS) is a debilitating skin disease, with pain being the most impactful symptom. Treatment options are limited; bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, was studied… read more here.

Keywords: q2w; bkz; week; q4w ... See more keywords

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.2527

Abstract: 2527 Background: QLS31905 is a Claudin18.2/CD3 bispecific antibody. Here we report the updated data of a phase 1 study of QLS31905. Methods: This multicenter phase 1 trial (NCT05278832) recruited patients (pts) with advanced solid tumors… read more here.

Keywords: q2w; data phase; stage; 1200 q2w ... See more keywords

Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT

Sign Up to like & get
recommendations! Published in 2024 at "Neurology"

DOI: 10.1212/01.wnl.0001050932.32807.8a

Abstract: Objective The phase 3b ADAPT NXT study (NCT04980495) investigated the efficacy, safety, and tolerability of efgartigimod administered either every other week (Q2W) or in fixed cycle dosing regimens. Background Individualized dosing of efgartigimod, a human… read more here.

Keywords: week; q2w; adapt nxt; fixed cycle ... See more keywords